---
document_datetime: 2025-12-03 10:50:03
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/keytruda-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: keytruda-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.360241
conversion_datetime: 2025-12-19 06:28:44.195719
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Keytruda

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type II /  | C.I.6 Change(s) to therapeutic indication(s) | 18/09/2025                          | 24/10/2025                                  | SmPC, Annex                      | Please refer to Scientific Discussion 'Keytruda- |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000245108                      | - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include, KEYTRUDA as monotherapy, for the treatment of resectable locally advanced head and neck squamous cell carcinoma (HNSCC) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without cisplatin and then as monotherapy in adults whose tumours express PD- L1 with a CPSâ‰¥1, based on the results of study P689V01MK3475 (KEYNOTE-689); this is a Phase 3, randomised, open-label study evaluating pembrolizumab as neoadjuvant therapy and in combination with standard of care as adjuvant therapy for stage III or IVA, resectable, locoregionally advanced head and neck squamous cell carcinoma. Consequently, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 46.0 To has also been submitted. In addition, Annex II.D has been updated, and the MAH took the opportunity to introduce   |            |            | II and PL           | EMA/VR/0000245108'   |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|----------------------|
| Extension of marketing authorisation / | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/09/2025 | 17/11/2025 | SmPC, Labelling and |                      |

<div style=\"page-break-after: always\"></div>

|                                       | 2. Changes to strength, pharmaceutical form and route of administration - (c) change or addition of a new strength/potency - Accepted 2. Changes to strength, pharmaceutical form and route of administration - (d) change or addition of a new pharmaceutical form - Accepted 2. Changes to strength, pharmaceutical form and route of administration - (e) change or addition of a new route of administration - Accepted Extension application to introduce a new pharmaceutical form (solution for injection) associated with two new strengths (790 mg and 395 mg) and new route of administration (subcutaneous use). The RMP (version 49.1) is updated in   |            | PL          |                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000264560 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC based on results from study KEYNOTE-158. This is a                                                                                                                                                                                                                                                                                                                                                          | 19/06/2025 | SmPC and PL | The updated results from study KEYNOTE-158 confirmed the data submitted at the time of approval of pembrolizumab monotherapy in patients with MSI-H/dMMR non-CRC solid tumors (endometrial, gastric, small intestine, and biliary cancers) who have disease progression on or following at least 1prior therapy. For more information, please refer to the Summary of Product |

<div style=\"page-break-after: always\"></div>

|                                          | Phase II study Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors. The MAH took also the opportunity to update the list of local representatives.                                                                                                                                                                                                                                   |            |     | Characteristics.   |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|
| Variation type II / EMA/VR/0000256845    | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.c The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - Accepted | 15/05/2025 | N/A |                    |
| Variation type IB / EMA/VR/0000246576    | B.I.e.5 Implementation of changes foreseen in an approved change management protocol - B.I.e.5.c Implementation of a change for a biological/immunological medicinal product - Accepted                                                                                                                                                                                                                  | 25/04/2025 | N/A |                    |
| Variation type IA_IN / EMA/VR/0000265039 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                                                           | 09/04/2025 | N/A |                    |